<DOC>
	<DOCNO>NCT00206102</DOCNO>
	<brief_summary>This Phase IV , randomize , parallel-group study design evaluate cataractogenic potential quetiapine fumarate ( SEROQUEL ) compare putative non-cataractogenic antipsychotic medication risperidone ( RISPERDAL ) . This study conduct fulfill SEROQUEL Phase IV commitment regard evaluation cataractogenic potential .</brief_summary>
	<brief_title>A Study Cataractogenic Potential Seroquel Risperdal Treatment Participants With Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Men woman age 18 65 Both Eyes present lens intact ( previous cataract extraction ) Stable place residency History corneal surgery Legal blindness ( define best correct visual acuity 20/200 bad one eye Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
</DOC>